Literature DB >> 32548712

The Prostate Cancer Outcomes (PCO) study in prostate cancer centres certified by the German Cancer Society.

Christoph Kowalski1, Günther Carl2, Günter Feick3, Simone Wesselmann4.   

Abstract

Since 2016, certified prostate cancer centres have been able to participate in the Prostate Cancer Outcomes (PCO) study. The aim of this study is to compare outcomes across centres after local treatment for prostate cancer. The study originated from a support group initiative and is jointly carried out by the German Cancer Society (Deutsche Krebsgesellschaft), the certification institute OnkoZert, patient support groups and the participating centres. So far, centres have been more successful at recruiting patients undergoing surgery than those receiving radiotherapy as the definitive treatment. This means that conclusions for the latter group of patients are almost impossible. It is important to us that all types of treatment are equally well represented in the study; thus, we encourage radiation therapists to participate in the PCO study.

Entities:  

Keywords:  Certification; Health Services Research; Patient Reported Outcome Measures; Quality Improvement; Variation

Year:  2020        PMID： 32548712     DOI： 10.1007/s00066-020-01655-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


  5 in total

1.  Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial.

Authors:  Elke Rammant; Piet Ost; Martijn Swimberghe; Barbara Vanderstraeten; Nicolaas Lumen; Karel Decaestecker; Renée Bultijnck; Gert De Meerleer; Camille Sarrazyn; Roos Colman; Valérie Fonteyne
Journal:  Strahlenther Onkol       Date:  2018-11-07       Impact factor: 3.621

2.  Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.

Authors:  Daniel A Barocas; JoAnn Alvarez; Matthew J Resnick; Tatsuki Koyama; Karen E Hoffman; Mark D Tyson; Ralph Conwill; Dan McCollum; Matthew R Cooperberg; Michael Goodman; Sheldon Greenfield; Ann S Hamilton; Mia Hashibe; Sherrie H Kaplan; Lisa E Paddock; Antoinette M Stroup; Xiao-Cheng Wu; David F Penson
Journal:  JAMA       Date:  2017-03-21       Impact factor: 56.272

3.  ["Expanded prostate cancer index composite" (EPIC-26): Results of functional treatment in patients with localized prostate cancer].

Authors:  B Beyer; H Huland; G Feick; M Graefen
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

4.  Defining a standard set of patient-centered outcomes for men with localized prostate cancer.

Authors:  Neil E Martin; Laura Massey; Caleb Stowell; Chris Bangma; Alberto Briganti; Anna Bill-Axelson; Michael Blute; James Catto; Ronald C Chen; Anthony V D'Amico; Günter Feick; John M Fitzpatrick; Steven J Frank; Michael Froehner; Mark Frydenberg; Adam Glaser; Markus Graefen; Daniel Hamstra; Adam Kibel; Nancy Mendenhall; Kim Moretti; Jacob Ramon; Ian Roos; Howard Sandler; Francis J Sullivan; David Swanson; Ashutosh Tewari; Andrew Vickers; Thomas Wiegel; Hartwig Huland
Journal:  Eur Urol       Date:  2014-09-16       Impact factor: 20.096

5.  Cohort profile: the TrueNTH Global Registry - an international registry to monitor and improve localised prostate cancer health outcomes.

Authors:  Sue M Evans; Jeremy L Millar; Caroline M Moore; John D Lewis; Hartwig Huland; Fanny Sampurno; Sarah E Connor; Paul Villanti; Mark S Litwin
Journal:  BMJ Open       Date:  2017-11-28       Impact factor: 2.692
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.